Not Yet Recruiting
The RELIEF study will evaluate the initial safety and effectiveness of using Irreversible Electroporation (IRE) for the treatment of symptomatic benign prostatic hyperplasia (BPH).
Irreversible Electroporation (IRE) for the Treatment of Lower Urinary Tract Symptoms (LUTS) in Men with Benign Prostatic Hyperplasia (BPH)
This pilot study will evaluate the initial safety and effectiveness of Irreversible Electroporation (IRE) using the NanoKnife System for the treatment of symptomatic benign prostatic hyperplasia (BPH). It is a prospective, non-randomized study enrolling 40 subjects at up to five U.S. clinical sites, with follow-up through 5 years post-treatment.
Key Endpoints:
Full study information can be found on ClinicalTrials.gov under identifier NCT07640776.
Please fill out the fields below if you are looking to be contacted to learn more about the RELIEF study.
"*" indicates required fields
Important Risk Information: The NanoKnife System is an investigational device for the treatment of benign prostatic hyperplasia (BPH). It has not received FDA clearance or approval for this indication. This study is being conducted under an Investigational Device Exemption (IDE).
AngioDynamics, the AngioDynamics logo, NanoKnife and the NanoKnife logo are trademarks and/or registered trademarks of AngioDynamics, Inc., an affiliate or subsidiary.